Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|August 28, 2014

ISPE Previews Drug Shortages Prevention Plan

ISPE released an advance look at the Introductory Summary of its Drug Shortages Prevention Plan.

ISPE announced on Aug. 27 that it released a preview of its Drug Shortages Prevention Plan, developed by ISPE’s Drug Shortages Task Team, aimed at helping the pharmaceutical industry avoid drug shortages, identify root causes, create and sustain organizational cultures, and maintain a robust and reliable supply of medications to patients world-wide. The Introductory Summary to the Plan released on Aug. 27 provides a first look at what is covered in the complete Plan.

“Our goal is that the pharmaceutical industry will use the Plan not only to help them look holistically across the supply chain, but also as a roadmap to use in challenging their current processes, systems and practices and to identify potential gaps and risks,” said ISPE CEO and president, Nancy Berg.

According to Berg, ISPE’s 2013 study on drug shortages provided clear evidence that mitigating shortages requires a holistic approach that includes careful alignment of organizational aspects, people, as well as the technical aspects of process and production in understanding risks and signals indicating a drug shortage may be possible.

The ISPE Drug Shortages Task Team will release the complete Drug Shortages Prevention Plan during the 2014 ISPE Annual Meeting that will be held Oct. 12-15 in Las Vegas, Nevada, US.

Source: ISPE


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.